人脐带间充质干细胞联合抗病毒等方法治疗新型冠状病毒肺炎

Human Umbilical Cord Mesenchymal Stem Cells Treatment Combined with Anti-Virus and other Treatments for COVID-19

目的探讨人脐带间充质干细胞(hUCMSC)联合抗病毒等方法对新型冠状病毒肺炎(COVID-19)重症患者的治疗作用。方法在常规治疗的基础上,对1例70岁的女性COVID-19重症患者静脉输注三次异体人脐带间充质干细胞,并对其抑制炎症反应和组织损伤的作用进行研究。结果降低了主要炎症因子IL-6以及C-反应蛋白(CRP)等指标的水平,输注期间患者中性粒细胞与淋巴细胞的比值持续下降,T细胞、NK细胞和B细胞的绝对值持续回升,CT影像结果显示肺部的炎症反应逐渐消退;未见不良反应。结论异体人脐带间充质干细胞联合抗病毒等方法对COVID-19重症患者安全有效,值得进行更多的临床探索。

Objective To explore the therapeutic effects of human umbilical cord mesenchymal stem cells(h UCMSCs)combined with anti-virus and other treatments on a critical patient with COVID-19.Methods A70-year old female critical patient with COVID-19 was injected allogenic human umbilical cord mesenchymal stem cells for three times while the routine treatment was performed.The anti-inflammatory and tissue repair effects were investigated.Results No obvious side effect was observed in the treatment of hUCMSCs.Major inflammatory cytokine IL-6 and tissue injuring marker CRP were decreased after the injection.The ratio of neutrophil to lymphocyte,T cell count,NK cell count and B cell count were gradually increased during the h UCMSCs treatment.The CT images indicated that lung inflammation was also gradually decreased.Conclusion The combination of human umbilical cord mesenchymal stem cells and anti-virus and other treatments is safe and effective for critical patients with COVID-19,which is worthy of further clinical exploration.